文献速递脑血管病外科神经重症

脑膜中动脉栓塞后慢性硬膜下血肿消退与功能恢复的时间关系

Temporal relationship between hematoma resolution and functional recovery after middle meningeal artery embolization for chronic subdural hematoma.
PubMed 文献 · J Neurosurg · 2026-05-22

该多中心回顾性研究纳入24中心2019–2024年接受脑膜中动脉栓塞(MMAE)的1781例慢性硬膜下血肿(cSDH)患者(2295个血肿),分析血肿消退与功能恢复的时间轨迹。血肿厚度呈指数衰减,估计消退50%需1.8个月、80%需8.9个月;完全消退者良好功能结局比例高于极少量消退者(68.9% vs 35.0%,p<0.001)。

要点

  • MMAE后血肿厚度呈可预测的指数衰减,消退50%约1.8个月、80%约8.9个月。
  • 90天内达到≥73%消退与更好功能结局相关(76.9% vs 67.3%,p<0.001)。
  • 神经系统恶化是缺乏良好结局的最强预测因素(23.7% vs 82.4%,p<0.001)。

核心结论

  • MMAE后cSDH血肿厚度消退遵循可预测的指数衰减模式。
  • 消退程度更大(≥80%)且速度更快(90天内)是有价值的预后指标。
  • 术后功能结局在6–12个月内逐步改善。

研究设计与样本

  • 真实世界多中心回顾性研究,纳入24个中心2019–2024年接受MMAE治疗的cSDH患者。
  • 共分析1781例患者、2295个cSDH,平均年龄72.8±12.4岁,男性占68.1%。

主要发现

  • 初始平均血肿厚度15.31±6.53 mm,末次随访降至5.24±5.91 mm,平均消退64.3%±42.1%。
  • 估计消退50%时间为1.8个月,消退80%时间为8.9个月。
  • 完整随访的2224例患者中1031例(46.4%)实现完全消退。
  • 中位mRS从基线1(0–3)改善至>12个月的0(0–2)。
  • 完全消退者良好功能结局比例高于极少量消退者(68.9% vs 35.0%,p<0.001)。

关键数值与推荐

  • 良好功能结局定义为mRS评分≤2。
  • 完全消退定义为≥99%;其余按剩余分布四分位分为显著(73%–98%)、中度(53%–73%)、部分(27%–53%)、极少量(<27%)。
  • 90天内达到≥73%消退者良好结局比例为76.9%,未达到者为67.3%(p<0.001)。
  • 神经系统恶化者良好结局比例为23.7%,无恶化者为82.4%(p<0.001)。

临床怎么用

  • 可利用指数衰减模型预估MMAE后血肿消退时间,辅助随访计划制定。
  • 90天内消退≥73%可作为评估治疗反应的量化参考。
  • 术后出现神经系统恶化提示预后不良,需加强监测与干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective was to evaluate the trajectories of hematoma resolution and functional improvement after middle meningeal artery embolization (MMAE) for chronic subdural hematoma (cSDH), model the temporal pattern of cSDH resolution, and identify factors associated with favorable outcomes. METHODS: This real-world multicenter retrospective study included cSDH patients treated with MMAE at 24 centers between 2019 and 2024. Hematoma thickness was measured at baseline and at follow-up intervals (1-4 weeks, 1-3 months, 3-6 months, 6-12 months, and > 12 months after embolization). Resolution patterns were modeled using exponential decay functions. Modified Rankin Scale (mRS) scores assessed functional outcomes. Good functional outcome was defined as mRS score ≤ 2. Resolution patterns were modeled using exponential decay functions to estimate time to 50% and 80% reduction. Patients were categorized as complete resolution (≥ 99%) or by quartile of the remaining distribution (substantial [73%-98%], moderate [53%-73%], partial [27%-53%], minimal [< 27%]). The primary outcome was good functional status (mRS score ≤ 2). RESULTS: The authors analyzed a total of 1781 patients with 2295 cSDHs who underwent MMAE. The mean ± SD age was 72.8 ± 12.4 years and 68.1% of patients were male. The initial mean hematoma thickness was 15.31 ± 6.53 mm, decreasing to 5.24 ± 5.91 mm at final follow-up (mean reduction 64.3% ± 42.1%). Resolution followed an exponential decay pattern, with an estimated time to 50% reduction of 1.8 months and to 80% reduction of 8.9 months. Complete resolution occurred in 1031 of 2224 patients (46.4%) with complete follow-up. The median (IQR) mRS score improved from 1 (0-3) at baseline to 0 (0-2) at > 12 months. Good functional outcomes were more common in patients with complete versus minimal resolution (68.9% vs 35.0%, p < 0.001). Achieving ≥ 73% resolution within 90 days was associated with better outcomes (good outcome in 76.9% of those with ≥ 73% resolution vs 67.3% in those without, p < 0.001). Neurological deterioration was the strongest predictor of lack of good outcome (23.7% in patients with neurological deterioration vs 82.4% without, p < 0.001). CONCLUSIONS: After MMAE for cSDH, reduction in hematoma thickness follows a predictable exponential decay pattern. Greater extent (≥ 80%) and faster timing (within 90 days) of resolution are valuable prognostic indicators. Functional outcomes improve progressively through 6-12 months after the procedure. The relationship between resolution extent and functional outcomes provides quantitative benchmarks for evaluating treatment response.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. DeMessie B, Essibayi MA, Salim HA, et al. Temporal relationship between hematoma resolution and functional recovery after middle meningeal artery embolization for chronic subdural hematoma. J Neurosurg. 2026. PMID: 42172679. doi:10.3171/2025.12.JNS251884

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。